Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain.  Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity and demonstrated activity in bone cancer and related pain.  VBY-825, a prototype compound within this series, is an orally bioavailable, highly potent, reversible inhibitor of a subset of cathepsin proteases (including cathepsins S, K, L and B) that demonstrated protection from bone destruction and remodeling in this metastatic breast cancer model, as well as significant analgesic activity.  These preclinical data suggest that Virobay's spectrum-selective cathepsin inhibitors have potential therapeutic utility in the treatment of metastatic and primary bone cancer and cancer-related bone pain, with a mechanism of action that would be highly complementary to standard chemotherapy.

The data were presented in a poster, titled "Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer," by Holsinger, et al., at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, on Sunday, November 13th.

"These preclinical data provide a compelling demonstration of the therapeutic potential of Virobay's cathepsin inhibitors in bone cancer and bone cancer pain," said Robert Booth, PhD, Virobay's president and chief executive officer.  "The data demonstrate that the anti-tumorigenic and analgesic activity is due to the selective targeting of specific cathepsins that are known to facilitate osteolytic metastasis, bone invasion and bone matrix degradation.  We believe that these dat
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
... McGown, Ph.D. , Molecular Devices Corporation. 7/99 , ... , the first microplate reader equipped with a ... was also the first microplate reader capable of measuring ... microplate reader from a limited colorimetric filterbased instrument to ...
... Yan Zhang, Molecular Devices Corporation, 1311 Orleans Dr., Sunnyvale, CA 94089. , ... INTRODUCTION , ... Quantitation Kit from Molecular Probes in the Gemini XS, Gemini EM and ... from Molecular Devices. This assay is much more sensitive than traditional photometer ...
... Assay , Uses High Efficiency Fluorescence Polarization (HEFP) detection method ... extract and enzyme preparations , Requires no separation or wash ... , Introduction , ... Cyclic adenosine monophosphate (cAMP) is a second messenger involved in ...
Cached Biology Technology:UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 2UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 3UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 4UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 5UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 6Using the NanoOrange protein kit in the Gemini XS, Gemini EM and SpectraMax M2 microplate readers (MaxLine Application Note #22) 2Using the NanoOrange protein kit in the Gemini XS, Gemini EM and SpectraMax M2 microplate readers (MaxLine Application Note #22) 3Using the NanoOrange protein kit in the Gemini XS, Gemini EM and SpectraMax M2 microplate readers (MaxLine Application Note #22) 4cAMP DataFile: Homogenous Cyclic AMP detection using High Efficiency Fluorescence Polarization 2cAMP DataFile: Homogenous Cyclic AMP detection using High Efficiency Fluorescence Polarization 3
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2
... in German . When someone,s knee ... has been so badly damaged that the bones rub together ... cartilage tissue artificially so that patients with such knee problems ... to make tendons and blood vessels in the laboratory. The ...
... symptoms appear for someone to die from bacterial meningitis. ... of Nottingham have finally discovered how the deadly meningococcal ... defence mechanism and attack the brain. The ... meningitis and could save the lives of hundreds of ...
... ExcellGene SA, Monthey and Adolf Kühner AG, Birsfelden announce ... development of a revolutionary cell culture technology for scale ... As part of a long-term partnership the two companies ... task of growing mammalian cells for the production of ...
Cached Biology News:Non-wovens as scaffolds for artificial tissue 2Breakthrough in the treatment of bacterial meningitis 2ExcellGene and Khner achieved milestone in development of novel 250 Liter mammalian cell culture bioreactors 2ExcellGene and Khner achieved milestone in development of novel 250 Liter mammalian cell culture bioreactors 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... for covering tissue sections and cell preparations immunohistochemically ... insoluble end products. UltraMount Plus can ... or AEC that require an aqueous mounting medium, ... No heating is required prior to use. This ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Buffer III is intented ... of PBMCs (or lysed ... for intracellular kinases and ... Applications: Intracellular Staining ...
Biology Products: